Health
FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile
Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy®, Wegovy® HD (semaglutide) injection 7.2 mg, which demonstrated substantial weight loss in adults with obesity in the STEP UP trial.1,2Wegovy® HD can be used along with a reduced calorie diet and increased physical activity to help adults with obesity lose weight and keep it off, provided they have tolerated the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinicall
About this update from Novo Nordisk A/s Class B
[{"type":"list","items":[{"val":[{"type":"text","content":"Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment* with Wegovy® HD (~19% regardless of whether patients stayed on treatment**) in the STEP UP trial1","length":197,"tagName":"p"}]},{"val":[{"type":"text","content":"In the STEP UP trial, about one in three trial participants taking Wegovy® HD achieved 25% weight loss or higher1","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"This approval for Wegovy® further expands its already robust label inclusive of multiple formulations, including Wegovy® pill, and indications not available with other GLP-1 weight loss medicines","length":195,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":505,"olType":false},{"type":"text","content":"PLAINSBORO, N.J., March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy®, Wegovy® HD (semaglutide) injection 7.2 mg, which demonstrated substantial weight loss in adults with obesity in the STEP UP trial.1,2 Wegovy® HD can be used along with a reduced calorie diet and increased physical activity to help adults with obesity lose weight and keep it off, provided they have tolerated the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated. This new update supplements the existing Wegovy® label, which also has distinct indications for Wegovy® not offered by any other GLP-1 medication for weight loss.2","length":736,"tagName":"p"},{"type":"text","content":""We are excited to bring Wegovy® HD injection to adults with obesity who are looking for powerful weight loss, as no other weight loss medicine has been studied to show superiority to Wegovy® HD," said Jamey Millar, executive vice president, US Operations of Novo Nordisk. "In addition to significant weight loss, Wegovy® is the only GLP-1 for adults with obesity that is proven to reduce the risk of events such as stroke, heart attack, or cardiovascular death in those who also have known heart disease. Today's milestone expands the strong clinical profile of Wegovy® that includes multiple indications that no other GLP-1 for weight loss can claim."","length":677,"tagName":"p"},{"type":"text","content":"Prior to this approval, the highest approved dose of ...